/
XFOR
$4.23-$0.06 (-1.40%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$425.3M
99M shares
52-week range
$2.45 – $4.83
75% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-160.47
X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
www.x4pharma.com- Employees
- 45
- IPO / List date
- Nov 16, 2017
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds XFOR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 19,177 | $65.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-04-28 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded XFOR yet.
